U01 (NIH Research Project Cooperative Agreement)

U01 (Research Project Cooperative Agreement) shares R01’s purpose statement almost word for word — funding “a discrete, specified, circumscribed project to be performed by the named investigator(s)” — but its funding instrument is a cooperative agreement, not a grant. That single distinction changes NIH’s role after award: on a grant, NIH’s involvement is limited to standard monitoring and stewardship; on a cooperative agreement, NIH expects to be substantially involved in carrying out the project. U01s are one of several “U-series” cooperative-agreement activity codes NIH uses in place of the corresponding “R” code (a U01 instead of an R01) when that higher level of agency involvement is warranted.

Last verified 25 August 2026 against NIH Institute guidance on cooperative agreements (NIAID, NINDS) and NIDDK’s U01 FAQ.

What “Substantial NIH Staff Involvement” Means

Substantial involvement means NIH scientific or program staff will assist, guide, coordinate, or actively participate in project activities after the award is made — not merely monitor progress reports. NIH describes examples of substantial involvement as including: participating in study design, data collection, and data analysis and interpretation; approving a stage of a clinical trial or other collaborative project before the next stage can start; and coordinating the overall efforts of the project or providing training to grantee staff. Critically, the Principal Investigator still retains primary responsibility and the dominant role for planning, directing, and executing the project — NIH staff participate as a substantially involved partner, not as a co-director displacing the PI.

Why NIH Uses a Cooperative Agreement Instead of a Grant

NIH turns to the cooperative-agreement mechanism for high-priority research areas where the scope, coordination needs, or risk profile of the work benefit from active agency participation beyond standard stewardship — most commonly multi-site clinical trials, large observational or epidemiologic studies, and other collaborative projects where a stage-gated approval process, cross-site coordination, or shared protocol oversight materially improves the project’s chances of producing usable, comparable results across sites.

How U01 Differs from R01

U01 and R01 fund comparably scoped, investigator-led projects, but they differ in three practical ways that matter to a research administrator managing either: funding instrument (cooperative agreement vs. grant, which determines the level of post-award NIH involvement); origin (U01 opportunities generally do not arise from investigator-initiated applications the way R01s do — they are typically issued against a specific funding opportunity announcement built around a defined multi-site or coordinated research need); and award terms (duration and budget for a U01 are set by the individual funding opportunity rather than following R01’s standard 1-5 budget-period, uncapped-budget pattern). See CASRAI’s U01 vs. R01 comparison and the R01 (NIH Research Project Grant) entry for the fuller picture of how U01 sits alongside NIH’s other activity codes.

Why This Matters for Research Administration

Because NIH program staff are substantially involved rather than in a standard monitoring role, institutions managing a U01 award should expect a different administrative rhythm than an R01: staged approval checkpoints (particularly on multi-site clinical trial U01s, where a subsequent phase cannot begin without NIH sign-off), more frequent and more substantive programmatic contact with NIH staff, and coordination obligations if the award is part of a larger network of U01 sites reporting to the same funding opportunity. None of this changes the PI’s underlying responsibility for the science — it changes how closely NIH is embedded in executing it.

Frequently Asked Questions

What does U01 stand for?

U01 is NIH’s activity code for a Research Project Cooperative Agreement — the cooperative-agreement counterpart to the R01 research grant.

What is the main difference between a U01 and an R01?

Funding instrument. R01 is a grant, where NIH’s post-award role is standard monitoring and stewardship. U01 is a cooperative agreement, where NIH expects to be substantially involved in carrying out the project — for example in study design, data analysis, or approving each stage of a multi-site clinical trial.

Does the U01 Principal Investigator lose control of the project to NIH?

No. The PI retains primary responsibility and the dominant role for planning, directing, and executing the project. NIH staff participate as a substantially involved partner, not as a replacement for the PI’s leadership.

Can a researcher submit an investigator-initiated U01 application the way they would for an R01?

Generally no. Cooperative agreements typically do not result from investigator-initiated applications — U01 opportunities are usually issued against a specific NIH funding opportunity announcement built around a defined research need, such as a coordinated multi-site clinical trial.

What are typical uses of the U01 mechanism?

Multi-site or multi-center clinical trials, large epidemiologic or observational studies, and other collaborative research projects where staged NIH approval or cross-site coordination materially benefits the project.

References

• National Institute of Allergy and Infectious Diseases, “Applicants — Understand What a Cooperative Agreement FOA Signifies.”
• National Institute of Allergy and Infectious Diseases, “Just for ‘U’ — A Closer Look at Cooperative Agreements.”
• National Institute of Neurological Disorders and Stroke, “Cooperative Agreements.”
• National Institute of Diabetes and Digestive and Kidney Diseases, “U01 Frequently Asked Questions.”